Tuesday Jun 24
Affymax Board Announces Decision to Dissolve the Company
Based on the information the Company currently has available, which is subject to change, the Company estimates that the aggregate amount of the distribution to stockholders could be a few cents per share, based on 37,490,095 shares of common stock outstanding as of April 30, 2014 and the remaining cash of approximately $4 million as of May 2014.
Affymax, Inc. Drug Omontys Terminal As Takeda Pharmaceutical Co. Ltd. Switches Off Support
Affymax, Inc. And Takeda Pharmaceutical Co. Ltd. Announce Termination Of Omontys Product Collaboration And License Agreement Takeda will withdraw the Omontys U.S. New Drug Application CUPERTINO, Calif.-- --Affymax, Inc. and Takeda Pharmaceutical Company Limited Osaka, Japan announced today that their OmontysA product collaboration and license ... (more)
Affymax and Takeda Announce Termination of OmontysA (peginesatide)...
Affymax, Inc. and Takeda Pharmaceutical Company Limited Osaka, Japan announced today that their Omontys product collaboration and license agreement will terminate effective September 10, 2014.